207 related articles for article (PubMed ID: 37623002)
21. Development and Validation of Web-Based Nomograms to Precisely Predict Survival Outcomes of Non-metastatic Nasopharyngeal Carcinoma in an Endemic Area.
Yao JJ; Lin L; Gao TS; Zhang WJ; Lawrence WR; Ma J; Sun Y
Cancer Res Treat; 2021 Jul; 53(3):657-670. PubMed ID: 33285052
[TBL] [Abstract][Full Text] [Related]
22. A multidimensional nomogram combining overall stage, dose volume histogram parameters and radiomics to predict progression-free survival in patients with locoregionally advanced nasopharyngeal carcinoma.
Yang K; Tian J; Zhang B; Li M; Xie W; Zou Y; Tan Q; Liu L; Zhu J; Shou A; Li G
Oral Oncol; 2019 Nov; 98():85-91. PubMed ID: 31569054
[TBL] [Abstract][Full Text] [Related]
23. Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 Inhibitor.
Guo J; Yang Q; Jiang Q; Gu LW; Lin HX; Guo L
Nutrients; 2023 Oct; 15(19):. PubMed ID: 37836546
[TBL] [Abstract][Full Text] [Related]
24. A new prognostic model for predicting outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma receiving subsequent line (≥2 lines) anti-programmed death-1 monotherapy.
Li SC; Deng SW; Sun XS; Lan KQ; Guo CY; Lin DF; Liu LT; Liu SL; Mai HQ; Tang LQ
Oral Oncol; 2023 Apr; 139():106336. PubMed ID: 36827901
[TBL] [Abstract][Full Text] [Related]
25. Establishment and validation of a nomogram for predicting the benefit of concurrent chemotherapy in stage II nasopharyngeal carcinoma: A study based on a phase III randomized clinical trial with 10-year follow-up.
Sun XS; Li XY; Xiao BB; Liu SL; Chen QY; Tang LQ; Mai HQ
Oral Oncol; 2020 Jan; 100():104490. PubMed ID: 31790913
[TBL] [Abstract][Full Text] [Related]
26. Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma.
Zhang A; Zhong G; Wang L; Cai R; Han R; Xu C; Chen S; Sun P; Chen H
Cancer Cell Int; 2021 Sep; 21(1):518. PubMed ID: 34583688
[TBL] [Abstract][Full Text] [Related]
27. A nomogram model based on pre-treatment and post-treatment MR imaging radiomics signatures: application to predict progression-free survival for nasopharyngeal carcinoma.
Sun MX; Zhao MJ; Zhao LH; Jiang HR; Duan YX; Li G
Radiat Oncol; 2023 Apr; 18(1):67. PubMed ID: 37041545
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study.
Tang XR; Li YQ; Liang SB; Jiang W; Liu F; Ge WX; Tang LL; Mao YP; He QM; Yang XJ; Zhang Y; Wen X; Zhang J; Wang YQ; Zhang PP; Sun Y; Yun JP; Zeng J; Li L; Liu LZ; Liu N; Ma J
Lancet Oncol; 2018 Mar; 19(3):382-393. PubMed ID: 29428165
[TBL] [Abstract][Full Text] [Related]
29. Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma.
Zhang LL; Xu F; Song D; Huang MY; Huang YS; Deng QL; Li YY; Shao JY
JAMA Netw Open; 2020 Dec; 3(12):e2029882. PubMed ID: 33306119
[TBL] [Abstract][Full Text] [Related]
30. Construction and Validation of a Novel Nomogram to Predict the Overall Survival of Patients With Combined Small Cell Lung Cancer: A Surveillance, Epidemiology, and End Results Population-Based Study.
Jiang A; Liu N; Zhao R; Liu S; Gao H; Wang J; Zheng X; Ren M; Fu X; Liang X; Tian T; Ruan Z; Yao Y
Cancer Control; 2021; 28():10732748211051228. PubMed ID: 34632799
[TBL] [Abstract][Full Text] [Related]
31. Establishment and validation of a nomogram with intratumoral heterogeneity derived from
Gu B; Zhang J; Ma G; Song S; Shi L; Zhang Y; Yang Z
BMC Cancer; 2020 Jan; 20(1):37. PubMed ID: 31941465
[TBL] [Abstract][Full Text] [Related]
32. Developing a nomogram model and prognostic analysis of nasopharyngeal squamous cell carcinoma patients: a population-based study.
Liu K; Wang J
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12165-12175. PubMed ID: 37428250
[TBL] [Abstract][Full Text] [Related]
33. Prognostic score models for survival of nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy and chemotherapy.
Zeng L; Guo P; Li JG; Han F; Li Q; Lu Y; Deng XW; Zhang QY; Lu TX
Oncotarget; 2015 Nov; 6(36):39373-83. PubMed ID: 26415223
[TBL] [Abstract][Full Text] [Related]
34. Development of a prognostic model to identify the metastatic nasopharyngeal carcinoma patients who may benefit from chemotherapy combination PD-1 inhibitor.
Liu GY; Lu N; Bei WX; Li WZ; Liang H; Xia WX; Xiang YQ; Yao HR
Front Immunol; 2023; 14():1069010. PubMed ID: 36733479
[TBL] [Abstract][Full Text] [Related]
35. [Establishment and validation of a novel nomogram to predict overall survival after radical nephrectomy].
Xiong LB; Zou XP; Ning K; Luo X; Peng YL; Zhou ZH; Wang J; Li Z; Yu CP; Dong P; Guo SJ; Han H; Zhou FJ; Zhang ZL
Zhonghua Zhong Liu Za Zhi; 2023 Aug; 45(8):681-689. PubMed ID: 37580273
[No Abstract] [Full Text] [Related]
36. Nomogram based on immune-inflammatory indicators and age-adjusted charlson comorbidity index score to predict prognosis of postoperative parotid gland carcinoma patients.
Cheng H; Xu JH; He JQ; Wu CC; Li JF; Xu XL
BMC Oral Health; 2024 Jun; 24(1):718. PubMed ID: 38909208
[TBL] [Abstract][Full Text] [Related]
37. Nomogram to Predict Long-Term Overall Survival and Cancer-Specific Survival of Radiotherapy Patients with Nasopharyngeal Carcinoma.
Li Z; Li C; Yang D; Zhou Z; Kang M
Biomed Res Int; 2023; 2023():7126881. PubMed ID: 36704722
[TBL] [Abstract][Full Text] [Related]
38. Development and validation of a nomogram for predicting long-term overall survival in nasopharyngeal carcinoma: A population-based study.
Wu J; Zhou Q; Pan Z; Wang Y; Hu L; Chen G; Wang S; Lyu J
Medicine (Baltimore); 2020 Jan; 99(4):e18974. PubMed ID: 31977914
[TBL] [Abstract][Full Text] [Related]
39. Novel nomogram for predicting survival in advanced non-small cell lung cancer receiving anti-PD-1 plus chemotherapy with or without antiangiogenic therapy.
Wu Y; Lv C; Lin M; Hong Y; Du B; Yao N; Zhu Y; Ji X; Li J; Lai J
Front Immunol; 2023; 14():1297188. PubMed ID: 38022521
[TBL] [Abstract][Full Text] [Related]
40. Tumor residue in patients with stage II-IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein-Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose.
Huang YY; Zhou JY; Zhan ZJ; Ke LR; Xia WX; Cao X; Cai ZC; Deng Y; Chen X; Zhang LL; Huang HY; Guo X; Lv X
BMC Cancer; 2023 May; 23(1):410. PubMed ID: 37149594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
